MRS to Include Markers in Software to Identify Myriad Test Candidates | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics said today that Mammography Reporting Systems, a breast cancer tracking and reporting software service, will use risk markers to identify patients who might benefit from Myriad's BRACAnalysis test.

Myriad said that MRS will incorporate risk factors for hereditary breast cancer risk in its software, enabling more physicians at mammography screening centers to identify patients who may benefit from the Myriad test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.